- Trial phase
- Not found
- Time to market
- Not estimable - drug candidate not identified.
- Why 1/10
- No hard, dated catalyst exists for GLK-901 because the drug could not be identified as a Glaukos development candidate. ImpactScore defaults to the lowest tier.
GLK-901 could not be verified as a Glaukos drug candidate through any public source. Investors should treat this name with extreme caution and seek clarification from the company before assuming it represents a real development program. Glaukos's confirmed pipeline includes GLK-321 (Phase 2, Demodex blepharitis), GLK-401 (Phase 2, retinal diseases), and GLK-601 (Phase 2, corneal epithelial defects), among others.
Price Chart
Executive Summary
Extensive web research and internal database searches found no evidence that "GLK-901" is a drug candidate from Glaukos Corporation (NYSE: GKOS). The only references to "GLK-901" in public sources are for a SANY dishwashing detergent, unrelated to biotech. Glaukos has a well-documented pipeline of GLK-numbered candidates (GLK-101 through GLK-601), but GLK-901 does not appear in any SEC filings, clinical trial registries, press releases, investor presentations, or analyst reports. This drug name could not be verified as a real Glaukos development asset.
How It Works
Not applicable - this drug candidate could not be identified in any public source related to Glaukos.
Trial Status
No clinical trials, press releases, SEC filings, or pipeline disclosures referencing GLK-901 were found for Glaukos.
The Two-Sided Case
Upcoming Catalysts
- None identified - GLK-901 is not a confirmed Glaukos pipeline asset.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
GLAUKOS Corp 8-K GKOS ·Originating report